ArticleActa parasitologica2026
First Molecular Characterization of Aelurostrongylus abstrusus in a Naturally Infected Domestic Cat in Belgrade, Serbia: In-Depth Clinical, Radiological and Parasitological Findings.
Article in Acta parasitologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeIn the past decade, the emergence of feline metastrongyloid lungworms has been increasingly recognized across Europe. The parasite is now being reported in previously non-endemic areas, with severe clinical cases described more frequently. This study describes the first molecular identification of Aelurostrongylus abstrusus in a naturally infected domestic cat in Serbia and treatment efficacy clinical and parasitological follow up.
methodsNested PCR targeting specific 233-bp long fragment of the internal transcribed spacer 2 region was used for species identification, which was further confirmed by sequence analysis. The animal was treated with 50 mg/kg fenbendazole orally during 15 days. The efficacy of treatment was monitored by examining the presence of larvae in faecal samples each day throughout the course of therapy by using Baerman technique.
resultsFenbendazole has shown to be effective in eliminating parasites, with larvae being completely absent from faecal samples by the 13th day of treatment. A worsening of clinical signs was observed following the initiation of therapy. The period of the highest larval burden in faecal samples correlated with the most intense coughing, which was also consistent with radiographic findings in the form of alveolar patterns. An additional experiment was done, showing that larvae can survive fluctuating daily temperatures in liquid environment for up to 51 days.
conclusionThe findings in this study indicate the emergence of feline lungworms and underscore its inclusion in differential diagnoses of feline respiratory syndrome. The importance of close monitoring during therapy highlights the need for further research, particularly in relation to treatment and prevention.
Indexed as
Identifiers
42439960What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.